摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氧代环丁烷甲酸甲酯 | 695-95-4

中文名称
3-氧代环丁烷甲酸甲酯
中文别名
3-氧代环丁基羧酸甲酯;3-氧环丁烷甲酸甲酯;3-氧代环丁烷羧酸甲酯;3-氧代环丁羧酸甲酯;3-氧基环丁烷羧酸甲酯;3-氧代环丁烷基羧酸甲酯;3-羰基-环丁烷甲酸甲酯
英文名称
methyl 3-oxocyclobutanecarboxylate
英文别名
methyl 3-oxocyclobutane-1-carboxylate;3-oxocyclobutanecarboxylic acid methyl ester;methyl 3-carbonyl-cyclobutanecarboxylate
3-氧代环丁烷甲酸甲酯化学式
CAS
695-95-4
化学式
C6H8O3
mdl
MFCD00604222
分子量
128.128
InChiKey
IHLHSAIBOSSHQV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    188.0±33.0 °C(Predicted)
  • 密度:
    1.219g/ml

计算性质

  • 辛醇/水分配系数(LogP):
    -0.5
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.666
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2918300090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    2-8°C

SDS

SDS:7c0e7d4cb673a2efcb44230655d16e9b
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 3-oxocyclobutanecarboxylate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-oxocyclobutanecarboxylate
CAS number: 695-95-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H8O3
Molecular weight: 128.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-羰基-环丁烷甲酸甲酯可作为合成各种药物化合物的中间体,例如新型咪唑苯并氮杂类衍生物等。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氧代环丁烷甲酸甲酯 在 sodium tetrahydroborate 作用下, 以 甲醇 为溶剂, 反应 2.0h, 生成 3-Hydroxy-1-cyclobutancarbonsaeuremethylester
    参考文献:
    名称:
    [EN] 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS
    [FR] 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES EN TANT QU'INHIBITEURS DE JAK2
    摘要:
    本公开提供了6-杂芳氧基苯并咪唑和氮杂苯并咪唑化合物及其组合物,用于抑制JAK2。
    公开号:
    WO2021226261A1
  • 作为产物:
    描述:
    3-氧代环丁烷基羧酸甲醇硫酸 作用下, 以 为溶剂, 以92.2%的产率得到3-氧代环丁烷甲酸甲酯
    参考文献:
    名称:
    取代的杂芳基化合物及其组合物和用途
    摘要:
    本发明提供了取代的杂芳基化合物及其组合物和用途。所述化合物为式(I)所示的化合物或者式(I)所示化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或它的前药。本发明还提供了包含所述化合物的药物组合物,所述药物组合物可以调节蛋白激酶,尤其是Aurora激酶和JAK激酶的活性,用于预防、处理、治疗和减轻蛋白激酶,尤其是Aurora激酶和JAK激酶活性介导的疾病或紊乱。
    公开号:
    CN106478651B
点击查看最新优质反应信息

文献信息

  • [EN] CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] DÉRIVÉS DE CHROMAN-4-ONE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
    申请人:HOFFMANN LA ROCHE
    公开号:WO2020120642A1
    公开(公告)日:2020-06-18
    The present invention provides compounds having the general formula (I) wherein R1 to R10, Gi, G2, X and m are as described herein, compositions including the compounds and methods of using the compounds for treating hepatitis B.
    本发明提供具有一般式(I)的化合物,其中R1至R10、Gi、G2、X和m如本文所述,包括这些化合物的组合物以及使用这些化合物治疗乙型肝炎的方法。
  • A photoredox catalyzed iminyl radical-triggered C–C bond cleavage/addition/Kornblum oxidation cascade of oxime esters and styrenes: synthesis of ketonitriles
    作者:Bin-Qing He、Xiao-Ye Yu、Peng-Zi Wang、Jia-Rong Chen、Wen-Jing Xiao
    DOI:10.1039/c8cc07072e
    日期:——
    A photoredox-catalyzed iminyl radical-triggered C–C bond cleavage/addition/Kornblum oxidation cascade of cycloketone oxime esters and styrenes in DMSO is described. This three-component, one-pot procedure features mild conditions, a broad substrate scope, and high functional group tolerance, providing an efficient approach to access diversely functionalized ketonitriles.
    描述了在DMSO中环酮肟酯和苯乙烯的光氧化还原催化的亚氨基自由基引发的CC键断裂/加成/ Kornblum氧化级联反应。这种三组分一锅法具有温和的条件,宽泛的底物范围和较高的官能团耐受性,提供了一种有效的途径来获得功能多样的乙腈。
  • [EN] FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS À TITRE DE MODULATEURS DE S1P
    申请人:ABBVIE INC
    公开号:WO2017036978A1
    公开(公告)日:2017-03-09
    The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    这项发明涉及杂环化合物作为S1P调节剂,包括这种化合物的药物组合物,以及在治疗、缓解或预防由S1P受体介导的疾病或紊乱中的用途。
  • [EN] FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE<br/>[FR] COMPOSÉS DE FLAVONE POUR LE TRAITEMENT ET LA PRÉVENTION D'UNE MALADIE CAUSÉE PAR LE VIRUS DE L'HÉPATITE B
    申请人:HOFFMANN LA ROCHE
    公开号:WO2020053249A1
    公开(公告)日:2020-03-19
    The present invention provides flavone derivatives having the general formula (I) which are useful for the treatment of Hepatitis B Virus infection (HBV). The compounds act as cccDNA (covalently closed circular DMA) inhibitors.
    本发明提供了具有通用公式(I)的黄酮衍生物,用于治疗乙型肝炎病毒感染(HBV)。这些化合物作为cccDNA(共价闭合环状DNA)抑制剂发挥作用。
  • [EN] ROR NUCLEAR RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS NUCLÉAIRES ROR
    申请人:ABBVIE INC
    公开号:WO2016198908A1
    公开(公告)日:2016-12-15
    The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
    本发明提供了式(I)化合物的药物可接受的盐、前药、生物活性代谢物、立体异构体和它们的同分异构体,其中变量如本文所述定义。本发明的化合物用于治疗免疫性疾病。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物